Perspective Therapeutics (NYSEAMERICAN:CATX) Releases Earnings Results

Perspective Therapeutics (NYSEAMERICAN:CATX) announced its quarterly earnings data on Monday. The company reported ($0.51) earnings per share for the quarter, FiscalAI reports. The firm had revenue of $0.04 million for the quarter. Perspective Therapeutics had a negative return on equity of 40.03% and a negative net margin of 9,841.86%.

Perspective Therapeutics Trading Down 5.2%

Shares of NYSEAMERICAN:CATX opened at $4.95 on Wednesday. The company’s fifty day moving average is $4.26 and its 200-day moving average is $3.42. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.66 and a current ratio of 8.66. Perspective Therapeutics has a 52 week low of $1.60 and a 52 week high of $6.16.

Hedge Funds Weigh In On Perspective Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CATX. Aigen Investment Management LP acquired a new stake in shares of Perspective Therapeutics in the fourth quarter valued at approximately $28,000. Russell Investments Group Ltd. lifted its holdings in Perspective Therapeutics by 184.1% during the 3rd quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company’s stock worth $29,000 after buying an additional 5,475 shares in the last quarter. nVerses Capital LLC acquired a new position in Perspective Therapeutics during the 4th quarter worth $31,000. AXQ Capital LP boosted its position in Perspective Therapeutics by 24.2% in the 4th quarter. AXQ Capital LP now owns 12,749 shares of the company’s stock valued at $35,000 after buying an additional 2,481 shares during the last quarter. Finally, Engineers Gate Manager LP bought a new position in Perspective Therapeutics in the 4th quarter valued at $35,000. 54.66% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

CATX has been the subject of several research reports. UBS Group reaffirmed a “buy” rating and issued a $7.00 target price (down from $18.00) on shares of Perspective Therapeutics in a research report on Friday, November 21st. BTIG Research reissued a “buy” rating and issued a $14.00 price target on shares of Perspective Therapeutics in a report on Tuesday. B. Riley Financial dropped their price objective on shares of Perspective Therapeutics from $12.00 to $11.00 and set a “buy” rating for the company in a research note on Tuesday, November 18th. HC Wainwright lifted their target price on shares of Perspective Therapeutics from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Friday, January 30th. Finally, Piper Sandler assumed coverage on shares of Perspective Therapeutics in a research note on Thursday, February 19th. They issued an “overweight” rating and a $16.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the stock. Based on data from MarketBeat, Perspective Therapeutics has an average rating of “Buy” and an average price target of $12.13.

Key Headlines Impacting Perspective Therapeutics

Here are the key news stories impacting Perspective Therapeutics this week:

• Positive Sentiment: Updated [212Pb]VMT-α-NET data accepted for a poster at the AACR Annual Meeting (presentation scheduled April 20). Prior interim data showed no dose‑limiting toxicities, no serious renal issues, and encouraging anti‑tumor activity (76% without progression in an analyzed cohort), which supports the program’s clinical momentum and visibility in oncology. AACR Data Acceptance
• Positive Sentiment: BTIG Research reaffirmed a “Buy” rating and set a $14 price target, signaling continued analyst conviction and providing upside vs. current levels. BTIG Reaffirmation
• Neutral Sentiment: Perspective issued a full-year 2025 results and business highlights update describing progress across its neuroendocrine, melanoma and solid tumor programs and growth of regional finishing facilities; useful for monitoring program cadence but not a near-term revenue driver. Full Year 2025 Results
• Neutral Sentiment: The company is scheduled to release its quarterly earnings on Wednesday — an event that could trigger near-term volatility as investors parse operational and cash‑flow details. Earnings Release Notice
• Negative Sentiment: Latest quarter: reported a ($0.51) EPS and only $0.04M in revenue, with very negative margins and ROE — highlighting ongoing cash burn and dependence on financing or milestones to fund development. This is the principal near‑term negative catalyst pressuring the stock. Quarterly Results
• Negative Sentiment: RBC cut its price target from $18 to $14 (still an Outperform) — a downward revision that tempers upside expectations despite the maintained positive rating. RBC Target Cut

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.